Wednesday - July 29, 2026
ESCMID: Sanofi's Nuvaxovid COVID-19 Vaccine Showed Better Tolerability Than MNEXSPIKE in Head-to-head Study
April 18, 2026
PARIS, France, April 18 (TNSxrep) -- Sanofi, a life sciences company, issued the following news release:

* * *

Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

* First head-to-head, double-blind, randomized phase 4 study powered to directly compare the tol . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products